| Budget Amount *help |
¥27,690,000 (Direct Cost: ¥21,300,000、Indirect Cost: ¥6,390,000)
Fiscal Year 2013: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2012: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2011: ¥12,350,000 (Direct Cost: ¥9,500,000、Indirect Cost: ¥2,850,000)
|
|---|
| Research Abstract |
The pathogenesis of bone destruction associated with chronic inflammation such as rheumatoid arthritis relied on two phases; abnormal immune responses and dysregulation of bone system. I've found that the transcription regulatory factor IkappaBzeta regulates Th17 development and is expressed in several bone cells. Thus, in this study, I attempted to determine the potential of IkappaBzeta as a therapeutic target for the treatment of inflammation-associated bone destruction, using genetically modified mice. Furthermore, I tried to identify a novel target cell/ factor that regulates both inflammation and bone destruction in arthritis. This study may provide the molecular basis for a new therapeutic strategy to block not only Th17-mediated inflammation but also osteoclastic bone destruction.
|
